A landmark study has shown lecanemab treatment to slow the course of Alzheimer’s disease. Lecanemab is now under consideration by the FDA but is not yet approved or available commercially.
Dr. Kiran T. Thakur is an inpatient neurologist at Columbia University Irving Medical Center, with clinical expertise in neuroinfectious diseases and neuroimmunology.
Jinsy Andrews, an associate professor in the Department of Neurology at the Vagelos College of Physicians and Surgeons, speaks about the big difference between Aduhelm and AMX0035.
Students from historically Black colleges and universities (HBCUs) joined Columbia biomedical research laboratories for a summer of science, as part of CUIMC’s newest summer program
"Hispanics and individuals of African ancestry have been significantly underrepresented in research of Alzheimer’s disease, although engaging underserved minorities is critical..." says Dr. Reitz
